drugset / Trial / NCT00422149

Twin SUBLIVAC® Grasses Clinical Efficacy Study

NCT00422149 ↗

Phase 3 Completed 350 enrolled HAL Allergy
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To show that treatment with SUBLIVAC® Grasses is clinically effective by means of reduction in allergic symptoms and/or use of allergic symptomatic medication in subjects suffering from IgE mediated allergic complaints triggered by grass pollen.

Timeline

Start
2006-09
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator SUBLIVAC® Grasses Unknown 10 unknown Subcutaneous